Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Dermatology Specialists Research
mi
from
Louisville, KY
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Dermatology Specialists Research
mi
from
Louisville, KY
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Radiant Research, Inc.
mi
from
Akron, OH
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Radiant Research, Inc.
mi
from
Akron, OH
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Oregon Medical Research Center, PC
mi
from
Portland, OR
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Oregon Medical Research Center, PC
mi
from
Portland, OR
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Philadelphia Institute of Dermatology
mi
from
Fort Washington, PA
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Philadelphia Institute of Dermatology
mi
from
Fort Washington, PA
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Omega Medical Research
mi
from
Warwick, RI
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Omega Medical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Research Across America
mi
from
Northeast, TX
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Research Across America
mi
from
Northeast, TX
Click here to add this to my saved trials
Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis
Effect of Topical Application of Sulforaphane- Containing Broccoli Sprout Extracts on Radiation Dermatitis During External-beam Radiation Therapy for Breast Cancer
Status: Enrolling
Updated:  11/15/2012
Johns Hopkins University
mi
from
Baltimore, MD
Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis
Effect of Topical Application of Sulforaphane- Containing Broccoli Sprout Extracts on Radiation Dermatitis During External-beam Radiation Therapy for Breast Cancer
Status: Enrolling
Updated: 11/15/2012
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Childhood Alopecia Areata Study Using the 308-nm Excimer Laser
Childhood Alopecia Areata Study: Part 1: Feasibility of the 308-nm Excimer Laser in Treatment of Patch Type Alopecia Areata in Pediatric Patients
Status: Enrolling
Updated:  11/21/2012
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Childhood Alopecia Areata Study Using the 308-nm Excimer Laser
Childhood Alopecia Areata Study: Part 1: Feasibility of the 308-nm Excimer Laser in Treatment of Patch Type Alopecia Areata in Pediatric Patients
Status: Enrolling
Updated: 11/21/2012
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females
Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females
Status: Enrolling
Updated:  12/10/2012
Hahnemann University Hospital
mi
from
Philadelphia, PA
Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females
Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females
Status: Enrolling
Updated: 12/10/2012
Hahnemann University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A New Micrografting Technique for Vitiligo
A Randomized Controlled Pilot Study to Examine the Use of Micrografting, Using a Novel Grafting Technique for the Repigmentation of Vitiligo
Status: Enrolling
Updated:  12/17/2012
Mgh Curtis
mi
from
Boston, MA
A New Micrografting Technique for Vitiligo
A Randomized Controlled Pilot Study to Examine the Use of Micrografting, Using a Novel Grafting Technique for the Repigmentation of Vitiligo
Status: Enrolling
Updated: 12/17/2012
Mgh Curtis
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Total Skin and Beauty Dermatology Center
mi
from
Birmingham, AL
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Total Skin and Beauty Dermatology Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Parexel Early Phase
mi
from
Glendale, CA
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Parexel Early Phase
mi
from
Glendale, CA
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Odyssey Medispa
mi
from
Marina Del Rey, CA
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Odyssey Medispa
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Rady Children's Hospital
mi
from
San Diego, CA
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Rady Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
FXM Research Corp Miami
mi
from
Miami, FL
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
FXM Research Corp Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
FMX Research Miramar
mi
from
Miramar, FL
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
FMX Research Miramar
mi
from
Miramar, FL
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Meda Phase, Inc
mi
from
Newnan, GA
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Meda Phase, Inc
mi
from
Newnan, GA
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Deaconess Clinic, Inc.
mi
from
Evansville, IN
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Deaconess Clinic, Inc.
mi
from
Evansville, IN
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Dermatology Specialists
mi
from
Louisville, KY
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Dermatology Specialists
mi
from
Louisville, KY
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Hamzavi Dermatology
mi
from
Ft. Gratiot, MI
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Hamzavi Dermatology
mi
from
Ft. Gratiot, MI
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Somerset Skin Centre
mi
from
Troy, MI
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Somerset Skin Centre
mi
from
Troy, MI
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Skin Specialists, PC
mi
from
Omaha, NE
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Skin Specialists, PC
mi
from
Omaha, NE
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Academic Dermatology Associates
mi
from
Albuquerque, NM
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Academic Dermatology Associates
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Zoe Drealos, MD
mi
from
High Point, NC
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Zoe Drealos, MD
mi
from
High Point, NC
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
PMG Research of Wilmington
mi
from
Wilmington, NC
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
PMG Research of Wilmington
mi
from
Wilmington, NC
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Central Sooner Research
mi
from
Norman, OK
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Central Sooner Research
mi
from
Norman, OK
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Oregon Dermatology & Research Center
mi
from
Portland, OR
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Oregon Dermatology & Research Center
mi
from
Portland, OR
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Palmetto Clinical Trial Services, LLC
mi
from
Simpsonville, SC
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Palmetto Clinical Trial Services, LLC
mi
from
Simpsonville, SC
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Arlington Center for Dermatology
mi
from
Arlington, TX
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Arlington Center for Dermatology
mi
from
Arlington, TX
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Suzanne Bruce and associates P.A. The Center for skin Research
mi
from
Houston, TX
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Suzanne Bruce and associates P.A. The Center for skin Research
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Stephen Miller MD
mi
from
San Antonio, TX
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Stephen Miller MD
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Center for Clinical Studies
mi
from
Houston, TX
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
Dermatology Research Center
mi
from
Salt Lake City, UT
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
Dermatology Research Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated:  12/17/2012
The Education and Research Foundation, Inc.
mi
from
Lynchburg, VA
Dose Range Study of CD5789 in Acne Vulgaris
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Status: Enrolling
Updated: 12/17/2012
The Education and Research Foundation, Inc.
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients
Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy
Status: Enrolling
Updated:  12/18/2012
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients
Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy
Status: Enrolling
Updated: 12/18/2012
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated:  1/9/2013
Clinical Research Facility
mi
from
San Diego, CA
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated: 1/9/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated:  1/9/2013
Clinical Research Facility
mi
from
Denver, CO
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated: 1/9/2013
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated:  1/9/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated: 1/9/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated:  1/9/2013
Clinical Research Facility
mi
from
Baltimore, MD
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated: 1/9/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated:  1/9/2013
Clinical Research Facility
mi
from
Allentown, PA
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated: 1/9/2013
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated:  1/9/2013
Clinical Research Facility
mi
from
Beloit, WI
Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Allergic Subjects
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
Status: Enrolling
Updated: 1/9/2013
Clinical Research Facility
mi
from
Beloit, WI
Click here to add this to my saved trials
Effects of Acleara Needle Insert on Acne
A Clinical Trial Investigating the Effects of Acleara Needle Insert on Acne Vulgaris
Status: Enrolling
Updated:  1/9/2013
Charles County Dermatology Associates
mi
from
White Plains, MD
Effects of Acleara Needle Insert on Acne
A Clinical Trial Investigating the Effects of Acleara Needle Insert on Acne Vulgaris
Status: Enrolling
Updated: 1/9/2013
Charles County Dermatology Associates
mi
from
White Plains, MD
Click here to add this to my saved trials
Effects of Acleara Needle Insert on Acne
A Clinical Trial Investigating the Effects of Acleara Needle Insert on Acne Vulgaris
Status: Enrolling
Updated:  1/9/2013
Bellaire Dermatology Associates
mi
from
Bellaire, TX
Effects of Acleara Needle Insert on Acne
A Clinical Trial Investigating the Effects of Acleara Needle Insert on Acne Vulgaris
Status: Enrolling
Updated: 1/9/2013
Bellaire Dermatology Associates
mi
from
Bellaire, TX
Click here to add this to my saved trials
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated:  1/14/2013
Elite Clinical Studies
mi
from
Phoenix, AZ
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated: 1/14/2013
Elite Clinical Studies
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated:  1/14/2013
Center for Dermatology Clinical Research
mi
from
Fremont, CA
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated: 1/14/2013
Center for Dermatology Clinical Research
mi
from
Fremont, CA
Click here to add this to my saved trials
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated:  1/14/2013
Sc Clinical Research, Inc.
mi
from
Garden Grove, CA
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated: 1/14/2013
Sc Clinical Research, Inc.
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated:  1/14/2013
Alliance Research
mi
from
Long Beach, CA
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated: 1/14/2013
Alliance Research
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated:  1/14/2013
Silverberg Surgical and Medical Group
mi
from
Newport Beach, CA
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated: 1/14/2013
Silverberg Surgical and Medical Group
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated:  1/14/2013
Northern California Research
mi
from
Sacramento, CA
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.
Status: Enrolling
Updated: 1/14/2013
Northern California Research
mi
from
Sacramento, CA
Click here to add this to my saved trials